• AbbVie announced the acquisition of Apogee Therapeutics for approximately $10.9 billion in an all-cash transaction.
  • The deal is expected to expand AbbVie's immunology pipeline with clinical-stage therapies for inflammatory and immunological diseases, including those for atopic dermatitis and asthma.
  • ABBV is trading 3.1% up at $242.25, extending a strong multi-day rally.